Form 8-K BIOMARIN PHARMACEUTICAL For: Aug 21
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St climbs after Fed's Waller says he could support rate hold
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
RBC Capital Positive on BioMarin Pharma (BMRN) Following Talazoparib Sale (MDVN)
August 24, 2015 10:29 AM EDTRBC Capital affirms BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) with an Outperform rating and $145 price target after the company announced that it and Medivation (Nasdaq: MDVN) entered into an asset purchase agreement under which Medivation will acquire all worldwide rights to talazoparib (formerly referred to as BMN 673), a highly-potent, orally-available poly ADP ribose polymerase (PARP) inhibitor currently in a Phase 3 study for the treatment of... More
